This study is looking at advanced or metastatic solid tumours, which are cancers that have grown beyond their original location or spread to other parts of the body. The treatment being tested is IPN60300, which is given as a solution for infusion directly into a vein. This means the medication is delivered slowly through a needle placed in a vein, similar to how fluids are given in a hospital setting. The study is divided into different phases, with the first phase testing different doses of the medication to find the safest and most effective amount, and later phases looking at how well the medication works in people with specific types of tumours.
The purpose of the study is to evaluate the safety, tolerability, and how well IPN60300 works against tumours in adults who have received previous treatment that did not work or who have no other standard treatment options available. The study will also look at how the body processes the medication, how it affects the body, and whether the immune system develops a response to it. During the study, participants will receive IPN60300 in cycles that last 21 days each, and their health and tumour response will be monitored regularly through physical examinations, blood tests, and imaging scans to see if the tumours are shrinking, staying the same, or growing.
The study will track various outcomes including any side effects that occur, how many people respond to the treatment with their tumours shrinking or disappearing, and how long these responses last. Participants will be followed throughout their treatment and for a period after their last dose to ensure their safety and to gather complete information about how the medication works. The entire study is expected to last approximately three years, during which participants will have regular visits to assess their condition and response to treatment.
France 
Spain 
